Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer

Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, ... Read More